Purpose of this Study
We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with a solid tumor form of cancer
- Have disease that is inoperable, advanced, or metastatic
- The tumor tests positive for a KRAS G12D mutation
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will:
- Take the study drug by mouth once or twice every day
- Depending on which arm of the study you are in, you may also get standard anti-cancer drugs every 1 to 2 weeks
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
[J5J-OX-JZZA] A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00116471
NCT ID
NCT06586515
Phase
I
Enrollment Status
Open to Enrollment